化合物 Ixazomib Citrate|T2016|TargetMol

MLN9708
1201902-80-8

￥279 2mg 起订

￥413 5mg 起订

￥578 10mg 起订

上海更新日期：2024-09-23

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 化合物 Ixazomib Citrate

英文名称：: MLN9708

CAS号：: 1201902-80-8

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: ≥95%

产品类别：: 抑制剂

货号：: T2016

Product Introduction

Bioactivity

Name	MLN9708
Description	MLN2238 suppresses the chymotrypsin-like proteolytic (β5) site of the 20S proteasome(Ki50=0.93 nM, IC50=3.4 nM/). The biologically active form of MLN9708 (Ixazomib Citrate) is MLN2238 in aqueous solutions or plasma.
Cell Research	Calu-6 cells are cultured in MEM containing 10% FBS and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. For IC50 determinations, cells are treated with varying concentrations of Bortezomib or MLN2238 in DMSO (0.5% final, v/v) for 1 hour at 37 °C. For reversibility experiments, cells are treated with either 1 μM Bortezomib or MLN2238 for 30 minutes at 37 °C and then washed thrice in medium to remove the Bortezomib or MLN2238. Cells are incubated for an additional 4 hours at 37 °C, after which the medium is removed and replaced with fresh medium. (Only for Reference)
Kinase Assay	Kinase assay: Calu-6 cells are cultured in MEM containing 10% fetal bovine serum and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. Proteasome activity is assessed by monitoring hydrolysis of the chymotrypsin-like substrate Suc-LLVY-aminoluciferin in the presence of luciferase using the Proteasome-Glo assay reagents according to the manufacturer's instructions. Luminescence is measured using a LEADseeker instrument.
In vitro	在多种实体瘤和血液移植瘤中,MLN9708有抗癌活性.
In vivo	MLN9708与水溶液和血浆接触后, MLN9708快速水解为具有生物活性的MLN2238。MLN2238抑制20S蛋白酶体的糜蛋白酶类水解位点（IC50=3.4 nM,Ki=0.93 nM）。MLN2238也抑制20S蛋白酶体的caspase类水解的位点（IC50=31 nM）和胰蛋白酶类水解的位点（IC50=3.5 μM）。
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 93 mg/mL (179.8 mM)
Keywords	MLN 9708 \| MLN-9708 \| MLN9708
Inhibitors Related	Teneligliptin hydrobromide \| Bortezomib \| Sitagliptin \| Anagliptin \| TCH-165 \| Alloxan monohydrate \| Sitagliptin phosphate monohydrate \| 4'-Hydroxychalcone \| Vildagliptin \| Linagliptin \| Aprotinin \| Racecadotril
Related Compound Libraries	Anti-Cancer Approved Drug Library \| Anti-Cancer Active Compound Library \| Bioactive Compound Library \| Bioactive Compounds Library Max \| FDA-Approved & Pharmacopeia Drug Library \| HIF-1 Signaling Pathway Compound Library \| FDA-Approved Drug Library \| Drug Repurposing Compound Library \| Anti-Cancer Clinical Compound Library \| Anti-Cancer Drug Library

Ixazomib Citrate|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子